The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Secondary Endpoint Presentation
PAAB Code
1
Posts
1
Posters
23
Views
2
Watching
-
Section 3.1.10 of the code notes "Secondary endpoints should be identified as such and the primary endpoint of the study should be presented in close proximity when warranted." We are unclear about the "when warranted" portion of this statement. Assuming the primary outcome of a study was achieved, would the data/outcomes of this primary endpoint need to be specified if a secondary endpoint is the focus of a promotional tool, in a case when the study is not included in the product monograph? All other parameters of the study, such as patient population, indication, etc., are consistent with the product monograph.